Cargando…
Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental Parkinson’s disease: possible involvement of different binding sites at the PPARγ receptor
BACKGROUND: Neuroprotection with cannabinoids in Parkinson’s disease (PD) has been afforded predominantly with antioxidant or anti-inflammatory cannabinoids. In the present study, we investigated the anti-inflammatory and neuroprotective properties of VCE-003.2, a quinone derivative of the non-psych...
Autores principales: | García, Concepción, Gómez-Cañas, María, Burgaz, Sonia, Palomares, Belén, Gómez-Gálvez, Yolanda, Palomo-Garo, Cristina, Campo, Sara, Ferrer-Hernández, Joel, Pavicic, Carolina, Navarrete, Carmen, Luz Bellido, M., García-Arencibia, Moisés, Ruth Pazos, M., Muñoz, Eduardo, Fernández-Ruiz, Javier |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5771072/ https://www.ncbi.nlm.nih.gov/pubmed/29338785 http://dx.doi.org/10.1186/s12974-018-1060-5 |
Ejemplares similares
-
Development of An Oral Treatment with the PPAR-γ-Acting Cannabinoid VCE-003.2 Against the Inflammation-Driven Neuronal Deterioration in Experimental Parkinson’s Disease
por: Burgaz, Sonia, et al.
Publicado: (2019) -
Oral administration of the cannabigerol derivative VCE-003.2 promotes subventricular zone neurogenesis and protects against mutant huntingtin-induced neurodegeneration
por: Aguareles, José, et al.
Publicado: (2019) -
VCE-003.2, a novel cannabigerol derivative, enhances neuronal progenitor cell survival and alleviates symptomatology in murine models of Huntington’s disease
por: Díaz-Alonso, Javier, et al.
Publicado: (2016) -
The Cannabigerol Derivative VCE-003.2 Exerts Therapeutic Effects in 6-Hydroxydopamine-Lesioned Mice: Comparison with The Classic Dopaminergic Replacement Therapy
por: Rodríguez-Carreiro, Santiago, et al.
Publicado: (2023) -
Neuroprotection with the Cannabidiol Quinone Derivative VCE-004.8 (EHP-101) against 6-Hydroxydopamine in Cell and Murine Models of Parkinson’s Disease
por: Burgaz, Sonia, et al.
Publicado: (2021)